Quest Diagnostics/$DGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Quest Diagnostics
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Ticker
$DGX
Sector
Primary listing
NYSE
Industry
Health Care Providers & Services
Headquarters
Employees
50,500
ISIN
US74834L1008
Website
DGX Metrics
BasicAdvanced
$19B
21.68
$7.91
0.49
$3.05
1.87%
Price and volume
Market cap
$19B
Beta
0.49
52-week high
$182.38
52-week low
$137.71
Average daily volume
843K
Dividend rate
$3.05
Financial strength
Current ratio
1.44
Quick ratio
1.105
Long term debt to equity
90.899
Total debt to equity
93.284
Dividend payout ratio (TTM)
37.46%
Interest coverage (TTM)
5.86%
Profitability
EBITDA (TTM)
1,975
Gross margin (TTM)
33.04%
Net profit margin (TTM)
8.83%
Operating margin (TTM)
14.35%
Effective tax rate (TTM)
21.91%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
6.13%
Return on equity (TTM)
13.95%
Valuation
Price to earnings (TTM)
21.681
Price to revenue (TTM)
1.873
Price to book
2.77
Price to tangible book (TTM)
-5.27
Price to free cash flow (TTM)
18.022
Free cash flow yield (TTM)
5.55%
Free cash flow per share (TTM)
951.35%
Dividend yield (TTM)
1.78%
Forward dividend yield
1.87%
Growth
Revenue change (TTM)
9.38%
Earnings per share change (TTM)
6.41%
3-year revenue growth (CAGR)
-1.65%
10-year revenue growth (CAGR)
3.04%
3-year earnings per share growth (CAGR)
-19.35%
10-year earnings per share growth (CAGR)
8.43%
3-year dividend per share growth (CAGR)
6.57%
10-year dividend per share growth (CAGR)
8.33%
What the Analysts think about DGX
Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.
Bulls say / Bears say
Leerink Partners upgraded Quest Diagnostics to 'Outperform' in January 2025, indicating confidence in the company's growth prospects. (nasdaq.com)
Barclays raised its price target for Quest Diagnostics to $185 in April 2025, reflecting optimism about the company's future performance. (gurufocus.com)
Quest Diagnostics launched the AD-Detect™ blood test in April 2025, a significant innovation in Alzheimer's disease diagnostics, potentially expanding its market share. (prnewswire.com)
Analysts have maintained a 'Hold' rating on Quest Diagnostics, suggesting limited short-term upside potential. (markets.businessinsider.com)
The company faces challenges in transitioning post-COVID, with a significant drop in COVID-19 testing revenues impacting overall performance. (nasdaq.com)
Insider selling activity, such as the sale of 420 shares by SVP & CCO Mark E. Delaney, may raise concerns about internal confidence in the stock. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
DGX Financial Performance
Revenues and expenses
DGX Earnings Performance
Company profitability
DGX News
AllArticlesVideos
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings
Benzinga·3 months ago
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Benzinga·3 months ago
Quest beats quarterly profit estimates on strong demand for diagnostic tests
Reuters·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul21
Quest Diagnostics
Dividend·Payment
$0.80Per share
FAQs
What’s the current market cap for Quest Diagnostics stock?
Quest Diagnostics (DGX) has a market cap of $19B as of July 11, 2025.
What is the P/E ratio for Quest Diagnostics stock?
The price to earnings (P/E) ratio for Quest Diagnostics (DGX) stock is 21.68 as of July 11, 2025.
Does Quest Diagnostics stock pay dividends?
Yes, the Quest Diagnostics (DGX) stock pays dividends to shareholders. As of July 11, 2025, the dividend rate is $3.05 and the yield is 1.87%. Quest Diagnostics has a payout ratio of 37.46% on a trailing twelve-month basis.
When is the next Quest Diagnostics dividend payment date?
The next Quest Diagnostics (DGX) dividend payment is scheduled for July 21, 2025.
What is the beta indicator for Quest Diagnostics?
Quest Diagnostics (DGX) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.